Skip to content

Haemonetics HAE Plasma — Net revenues

Other segment segments

Hospital
$159.65M+8.0%
Blood Center
$56.41M+0.7%

Similar metrics at other companies

Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%
Perimeter Solutions logo
PRMRevenues from products — Net Sales
$122.57M+81.2%
Popular logo
BPOPPR — Net Revenue
$668.07M+9.5%
Sotera Health logo
SHCProduct — Total net revenues
$38.44M+25.7%
Neurocrine Biosciences logo
NBIXNet product sales — Total revenues
$811M+43.9%
Balchem logo
BCPCProduct Sales Revenue — Net Sales
$270.22M+8.1%

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's plasma — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's plasma — net revenues?
Haemonetics (HAE) reported plasma — net revenues of $130.29M in Q1 2026.
How has Haemonetics's plasma — net revenues changed year-over-year?
Haemonetics's plasma — net revenues increased by 2.8% year-over-year, from $126.74M to $130.29M.
What does plasma — net revenues mean?
Represents the total gross sales generated by the plasma segment, net of returns, allowances, and discounts. This is the primary indicator of the segment's market demand and top-line growth performance. It serves as the foundation for evaluating the segment's contribution to the overall corporate financial health.